Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.64 +0.1%	$12.47	$8.04 ▼ $25.88	$373.73M	2.27	421,186 shs	172,653 shs
FBIO Fortress Biotech	$1.91 +4.3%	$1.82	$1.33 ▼ $2.89	$55.59M	1.75	412,266 shs	180,983 shs
IDYA IDEAYA Biosciences	$22.09 +0.8%	$20.34	$13.45 ▼ $44.42	$1.94B	0.03	1.03 million shs	522,894 shs
MNPR Monopar Therapeutics	$35.87 +2.0%	$35.99	$1.72 ▼ $54.30	$221.68M	1.01	362,174 shs	24,007 shs
OVID Ovid Therapeutics	$0.34 +4.1%	$0.31	$0.24 ▼ $1.47	$24.06M	0.13	434,742 shs	283,192 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	+2.29%	+14.48%	+49.67%	-37.82%
FBIO Fortress Biotech	0.00%	+4.89%	+1.54%	+25.59%	+8.47%
IDYA IDEAYA Biosciences	0.00%	+3.37%	+4.69%	+50.17%	-33.64%
MNPR Monopar Therapeutics	0.00%	+6.76%	-5.63%	+19.57%	+919.90%
OVID Ovid Therapeutics	0.00%	+13.91%	+9.80%	+22.16%	-54.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	3.7667 of 5 stars	4.6	2.0	0.0	3.2	2.5	0.6
FBIO Fortress Biotech	2.149 of 5 stars	3.5	1.0	0.0	0.6	3.3	0.6
IDYA IDEAYA Biosciences	3.4697 of 5 stars	3.5	1.0	4.4	0.9	1.7	0.0
MNPR Monopar Therapeutics	3.0401 of 5 stars	3.4	5.0	0.0	2.7	1.7	0.0
OVID Ovid Therapeutics	4.3758 of 5 stars	3.6	3.0	4.6	1.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	296.04% Upside
FBIO Fortress Biotech	3.00	Buy	$21.00	1,000.05% Upside
IDYA IDEAYA Biosciences	2.93	Moderate Buy	$53.42	141.81% Upside
MNPR Monopar Therapeutics	2.80	Moderate Buy	$56.50	57.51% Upside
OVID Ovid Therapeutics	3.20	Buy	$3.13	808.43% Upside

Current Analyst Ratings Breakdown

Latest OVID, IDYA, FBIO, MNPR, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
5/22/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $66.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	2.43	N/A	N/A	$8.90 per share	1.53
FBIO Fortress Biotech	$57.67M	0.98	N/A	N/A	($0.06) per share	-31.82
IDYA IDEAYA Biosciences	$7M	276.38	N/A	N/A	$12.25 per share	1.80
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A
OVID Ovid Therapeutics	$548K	44.64	N/A	N/A	$0.96 per share	0.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
FBIO Fortress Biotech	-$46M	-$2.23	N/A	N/A	N/A	-71.24%	-4,712.53%	-27.67%	8/12/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.59	N/A	N/A	N/A	N/A	-29.28%	-27.68%	8/5/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.48	N/A	N/A	N/A	N/A	-55.39%	-51.53%	8/8/2025 (Estimated)
OVID Ovid Therapeutics	-$26.43M	-$0.35	N/A	N/A	N/A	-4,562.23%	-34.17%	-25.34%	8/12/2025 (Estimated)

Latest OVID, IDYA, FBIO, MNPR, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
5/13/2025	Q1 2025	OVID Ovid Therapeutics	-$0.14	-$0.14	N/A	-$0.14	$0.03 million	$0.13 million
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/6/2025	Q1 2025	IDYA IDEAYA Biosciences	-$0.75	-$0.82	-$0.07	-$0.82	$2.10 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	0.06	5.64	5.64
FBIO Fortress Biotech	1.74	1.72	1.55
IDYA IDEAYA Biosciences	N/A	13.92	13.92
MNPR Monopar Therapeutics	N/A	36.91	36.91
OVID Ovid Therapeutics	0.22	4.93	4.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
FBIO Fortress Biotech	96.51%
IDYA IDEAYA Biosciences	98.29%
MNPR Monopar Therapeutics	1.83%
OVID Ovid Therapeutics	72.24%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
FBIO Fortress Biotech	27.90%
IDYA IDEAYA Biosciences	2.50%
MNPR Monopar Therapeutics	20.50%
OVID Ovid Therapeutics	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
FBIO Fortress Biotech	170	29.57 million	21.32 million	Optionable
IDYA IDEAYA Biosciences	80	87.58 million	85.39 million	Optionable
MNPR Monopar Therapeutics	10	6.12 million	4.86 million	Not Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable

OVID, IDYA, FBIO, MNPR, and ARCT Headlines

Recent News About These Companies

Ovid Therapeutics Inc Chart - Morningstar

July 2, 2025 | morningstar.comM

Juneberry Farm in Ovid opens for u-pick season

July 1, 2025 | fingerlakes1.comF

Ovid man, 81, charged with DWI after near-crash

June 28, 2025 | fingerlakes1.comF

Ovid Therapeutics To Sell Future Royalties Of Ganaxolone For $7 Mln In Cash, Stock Up In Pre-Market - Nasdaq

June 27, 2025 | nasdaq.com

Ovid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 Million - Nasdaq

June 27, 2025 | nasdaq.com

Ovid Therapeutics Inc.: Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

June 25, 2025 | finanznachrichten.de

Ovid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 Million

June 25, 2025 | quiverquant.comQ

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

June 25, 2025 | globenewswire.com

Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?

June 20, 2025 | msn.com

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

June 5, 2025 | taiwannews.com.twT

Ovid Therapeutics Inc. to Host Event on Biomarkers in Epilepsy featuring Dr. Alexander Rotenberg

June 5, 2025 | quiverquant.comQ

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025 | globenewswire.com

PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics

May 8, 2025 | cambridgenetwork.co.ukC

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

May 6, 2025 | zacks.com

Ovid Police Chief, city accused of civil rights violations

April 24, 2025 | msn.com

Ovid Therapeutics (OVID) Receives a Buy from TD Cowen

April 23, 2025 | theglobeandmail.com

Biotech Leaders Implore Sen. Cassidy To Step Up in Wake of FDA Cuts

April 10, 2025 | biospace.comB

Ovid's Main Street Business Owners Are Speaking Out About Recovery Process After January Fire

April 5, 2025 | weny.comW

Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

April 2, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
By Jeffrey Neal Johnson | June 18, 2025
View Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
Government Mandate Sends eVTOL Stocks Flying
By Jeffrey Neal Johnson | June 10, 2025
View Government Mandate Sends eVTOL Stocks Flying
The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
By Jeffrey Neal Johnson | June 22, 2025
View The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
GitLab: Buy It Low While You Still Can—Higher Prices Are Coming
By Thomas Hughes | June 11, 2025
View GitLab: Buy It Low While You Still Can—Higher Prices Are Coming
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge

OVID, IDYA, FBIO, MNPR, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$13.64 +0.02 (+0.11%)

As of 07/3/2025 03:11 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Fortress Biotech NASDAQ:FBIO

$1.91 +0.08 (+4.32%)

As of 07/3/2025 03:36 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

IDEAYA Biosciences NASDAQ:IDYA

$22.09 +0.17 (+0.78%)

As of 07/3/2025 01:04 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Monopar Therapeutics NASDAQ:MNPR

$35.87 +0.71 (+2.02%)

Closing price 07/3/2025 01:04 PM Eastern

Extended Trading

$35.87 0.00 (0.00%)

As of 07/3/2025 04:23 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Ovid Therapeutics NASDAQ:OVID

$0.34 +0.01 (+4.08%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$0.35 +0.01 (+2.91%)

As of 07/3/2025 04:59 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time